FDA Expands Anktiva Use for BCG‑Unresponsive High‑Grade Papillary Bladder Cancer
The U.S. Food and Drug Administration announced on Oct. 14, 2026 that it is expanding the approved use of the drug Anktiva, given together with Bacillus Calmette‑Guérin (BCG), to treat adults with high‑grade papillary‑only bladder cancer that has not spread into the muscle and that did not respond to BCG.
This marks the first FDA‑approved therapy specifically for patients with BCG‑unresponsive, high‑grade papillary disease.
Why the FDA Changed Its Approach
The agency said it used a new approach that looks at scientific similarities between two forms of non‑muscle invasive bladder cancer (NMIBC): carcinoma in situ (CIS) and high‑grade papillary‑only disease. Because the two share key features, the FDA applied data from Anktiva’s earlier CIS approval to the new indication.
- 1Confirm diagnosis of high‑grade papillary‑only bladder cancer that is BCG‑unresponsive.
- 2Discuss Anktiva plus BCG with your urologist to see if you qualify.
- 3Begin the six‑week weekly treatment schedule and monitor for side effects.
- 4If cancer persists after a second six‑week course, consider alternative options such as surgery.
Source: U.S. Food and Drug Administration
How Anktiva Works and What the Data Show
Anktiva is delivered directly into the bladder through a catheter, once a week for six weeks, with additional courses based on response. In the trial that supported its original CIS approval, 62% of 77 patients achieved a complete response, and 58% of those maintained it for at least 12 months, 40% for at least 24 months.
Who Is Affected and What Steps to Take
Adults with high‑grade papillary‑only bladder tumors that have not responded to BCG can now receive Anktiva plus BCG. Treatment may continue for up to 37 months but must stop if the cancer persists after a second six‑week course, returns, progresses, or side effects become unacceptable. Patients should discuss with their urologist whether they meet the criteria and understand the treatment schedule.
Potential Risks and Safety Information
Common side effects include painful or frequent urination, urgency, blood in the urine, urinary‑tract infections, muscle or joint pain, chills, fever, and elevated blood creatinine or potassium. The prescribing information warns that delaying surgery to remove the bladder can allow the cancer to spread, which can be fatal.
Anyone considering this therapy should talk to a qualified attorney if they have questions about insurance coverage, potential liability, or need assistance navigating the medical‑legal aspects of cancer treatment.
What this means: our conclusions
- Good newsNew option for patients with limited treatment choices
The expanded approval gives a previously unavailable therapy to people whose tumors did not respond to standard BCG, potentially improving outcomes.
- RiskRisk of side effects and treatment limits
Patients must monitor for urinary and systemic side effects, and stop treatment if cancer persists after a second six‑week course.
- What to watchWatch for FDA guidance on BCG‑unresponsive NMIBC
The agency is finalizing draft guidance that could affect future drug approvals for similar bladder‑cancer indications.
- ContextImpact on insurance and coverage decisions
Health insurers may need to update policies to cover Anktiva for the newly approved indication, affecting out‑of‑pocket costs for patients.
- What to doTalk to a lawyer about coverage and liability
If you are considering Anktiva, consult an attorney to understand insurance benefits, potential disputes, and any legal steps needed for treatment.
| Parameter | Original CIS Approval | Expanded Papillary‑Only Approval |
|---|---|---|
| Indication | Carcinoma in situ (CIS) with/without papillary tumors | High‑grade papillary‑only NMIBC, BCG‑unresponsive |
| Treatment schedule | Weekly for six weeks, then based on response | Weekly for six weeks, up to 37 months, stop if persistent after second course |
Source: U.S. Food and Drug Administration
Find a lawyer for this issue
Federal rules apply nationwide, but your options depend on your state and situation. Browse attorneys by practice area, then pick your state.
This article is general information based on U.S. Food and Drug Administration and court or agency records available at publication time. It is not legal advice; laws and deadlines differ by state and by case. Published October 14, 2026.
Source: U.S. Food and Drug Administration
CVS to Pay $315 Million in Federal Opioid Settlement and Boost Monitoring
CVS Pharmacy will pay $315 million to settle DOJ claims it filled dubious opioid prescriptions and sought Medicare reimbursements, and will add new safeguards to monitor prescribing patterns.
FTC Secures Contract Change to Block Discriminatory T‑Shirt Pricing
The FTC closed its probe after Gildan Activewear and S&S Holdings amended their agreement to let Gildan set prices for any North American distributor, curbing discriminatory pricing.
Justice Department Launches Final Phase of Western Union Fraud Victim Compensation
The DOJ opened the third and last remission round, offering up to $3.4 million to 1,294 victims who sent money via Western Union between 2004 and 2020. Deadline Dec. 31.
Consumers petition Supreme Court to halt Paramount Skydance‑Warner Bros. Discovery merger
Five consumers filed an emergency petition with the U.S. Supreme Court on Oct. 5, 2026, urging justices to stop the $110 billion Paramount Skydance‑Warner Bros. Discovery merger before it closes on Tuesday.
State Abortion Shield Laws Face Direct Challenge in Supreme Court
States with strict abortion bans have filed a direct lawsuit in the Supreme Court against states protecting doctors who mail abortion pills.